NHS Framework Agreement for the supply of Ranibizumab for the NHS in England

The Procurement relates to the supply of ranibizumab an Anti Veg-F medicine used in medical retinal vascular services for the NHS in England. Anti Veg-F medicines are currently used in the treatment of: a. neovascular (wet) age-related macular degeneration (AMD); b. visual impairment due to diabetic macular oedema (DME/DMO); c. visual impairment due to myopic choroidal neovascularisation (myopic CNV); and d. visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).

Period of framework: 1 April 2023 to 31 March 2024 with an option to extend (at the Authority's discretion) for a further period (or periods) up to a total of 12 months (i.e. total possible framework duration of 24 months) Framework Reference Number: CMD/SCM/MJP/2023/01 Atamis Reference Number: C123966

http://health.atamis.co.uk/